Header Logo

Connection

CELESTINE TUNG to Bevacizumab

Back to Details
This is a "connection" page, showing publications CELESTINE TUNG has written about Bevacizumab.
CELESTINE TUNG
Connection Strength
0.035
Bevacizumab
  1. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.